GMAB – Genmab A/S

GMAB — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.6

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.26

EPS Last/This Y

-0.31

EPS This/Next Y

0.51

Price

51.72

Target Price

63.38

Analyst Recom

1.57

Performance Q

61.99

Upside

-20.9%

Beta

0.71

Ticker: GMAB

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	GMAB	36.9	0.29	0.37	100722
2026-10-15	GMAB	37.82	0.29	0.05	101372
2026-10-16	GMAB	36.99	0.29	1.81	102174
2026-10-19	GMAB	38.5	0.27	0.31	95179
2026-10-20	GMAB	39.07	0.26	0.93	94759
2026-10-21	GMAB	39.6	0.29	1.97	100147
2026-10-22	GMAB	39.99	0.30	2.39	100693
2026-10-23	GMAB	43.8	0.31	5.00	101885
2026-10-26	GMAB	44.69	0.31	0.43	102039
2026-10-27	GMAB	44.69	0.32	0.03	86551
2026-10-28	GMAB	57.33	0.27	0.25	101017
2026-10-29	GMAB	56.47	0.34	0.53	114158
2026-10-30	GMAB	57.02	0.35	0.10	118857
2026-11-02	GMAB	54.93	0.33	0.17	127168
2026-11-03	GMAB	55.52	0.32	0.08	131373
2026-11-04	GMAB	55.09	0.32	0.13	131373
2026-11-05	GMAB	52.69	0.32	0.28	134618
2026-11-06	GMAB	53.62	0.32	0.09	134476
2026-11-09	GMAB	55.8	0.32	0.03	134611
2026-11-10	GMAB	54.08	0.30	0.05	145086
2026-11-11	GMAB	53.87	0.30	0.59	145581
2026-11-12	GMAB	51.69	0.30	0.09	145156
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	GMAB	36.89	-	527.8	1.17
2026-10-15	GMAB	37.83	-	552.5	1.17
2026-10-16	GMAB	37.00	-	486.9	1.17
2026-10-19	GMAB	38.50	-	578.0	1.17
2026-10-20	GMAB	38.50	-	578.0	1.17
2026-10-21	GMAB	39.07	-	566.8	1.17
2026-10-22	GMAB	40.01	-	543.3	1.17
2026-10-23	GMAB	43.79	-	668.4	1.17
2026-10-26	GMAB	44.69	-	567.7	1.17
2026-10-27	GMAB	44.66	-	532.7	1.17
2026-10-28	GMAB	57.34	-	961.1	1.17
2026-10-29	GMAB	56.47	-	505.7	1.17
2026-10-30	GMAB	57.04	-	541.4	1.17
2026-11-02	GMAB	54.93	-	475.8	1.17
2026-11-03	GMAB	55.49	-	490.1	1.17
2026-11-04	GMAB	55.08	-	521.4	1.17
2026-11-05	GMAB	52.73	-	470.7	1.17
2026-11-06	GMAB	53.63	-	586.7	1.17
2026-11-09	GMAB	55.81	-	630.1	1.17
2026-11-10	GMAB	54.08	-	515.6	1.17
2026-11-11	GMAB	53.87	-	550.5	1.24
2026-11-12	GMAB	51.72	-	500.8	1.24
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	GMAB	0.00	0.35	1.03
2026-10-15	GMAB	0.00	0.35	1.03
2026-10-16	GMAB	0.00	0.35	1.03
2026-10-19	GMAB	0.00	0.25	1.03
2026-10-20	GMAB	0.00	0.25	1.03
2026-10-21	GMAB	0.00	0.25	1.03
2026-10-22	GMAB	0.00	0.25	1.03
2026-10-23	GMAB	0.00	0.25	1.03
2026-10-26	GMAB	0.00	0.29	1.03
2026-10-27	GMAB	0.00	0.29	1.12
2026-10-28	GMAB	0.00	0.29	1.12
2026-10-29	GMAB	0.00	0.29	1.12
2026-10-30	GMAB	0.00	0.29	1.12
2026-11-02	GMAB	0.00	0.25	1.12
2026-11-03	GMAB	0.00	0.25	1.12
2026-11-05	GMAB	0.00	0.25	1.12
2026-11-06	GMAB	0.00	0.25	1.12
2026-11-09	GMAB	0.00	0.19	0
2026-11-10	GMAB	0.00	0.19	1.09
2026-11-11	GMAB	0.00	0.19	1.60
2026-11-12	GMAB	0.00	0.19	1.60
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.56

Avg. EPS Est. Current Quarter

0.16

Avg. EPS Est. Next Quarter

0.3

Insider Transactions

Institutional Transactions

0.19

Beta

0.71

Average Sales Estimate Current Quarter

1249

Average Sales Estimate Next Quarter

1051

Fair Value

51.94

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

13.8

Max Drawdown 5-Year %

-61.8

Target Price

63.38

P/E

44.33

Forward P/E

31.54

PEG

1.49

P/S

7.41

P/B

5.02

P/Free Cash Flow

37.38

EPS

1.17

Average EPS Est. Cur. Y

1.24

EPS Next Y. (Est.)

1.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.96

Relative Volume

1.34

Return on Equity vs Sector %

-14.9

Return on Equity vs Industry %

4.6

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.11

EBIT Estimation

500.8

◆ GMAB Healthcare

$51.74

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

2/25

Volume

0/15

Valuation

12/20

TP/AR

3/10

Options

8/10

RSI

60.2

Range 1M

66.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

16/30

Estimates

8/20

Inst/Vol

8/15

Options

8/10

EPS Yr

-18.2%

EPS NY

30.5%

52W%

77.8%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +13.8% upside

Quality

13/30

Valuation

7/30

Growth

14/25

Stability

4/10

LT Trend

1/5

Upside

+13.8%

Quality

MoS

GMAB — P/E HistoricalBiotechnology

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 3244

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

GMAB

Latest News

—

Caricamento notizie per GMAB…

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.14

Margin Of Safety %

-3

Put/Call OI Ratio

0.68

EPS Next Q Diff

-0.03

EPS Last/This Y

-0.4

EPS This/Next Y

-0.1

Price

40.65

Target Price

54.57

Analyst Recom

2.75

Performance Q

-11.4

Upside

26.9%

Beta

0.71

Ticker: NVO

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	NVO	38.12	0.63	0.86	1541320
2026-10-15	NVO	39.24	0.63	0.80	1547006
2026-10-16	NVO	38.81	0.63	0.56	1550654
2026-10-19	NVO	38.41	0.64	1.86	1381743
2026-10-20	NVO	39.34	0.68	0.48	1433087
2026-10-21	NVO	39.07	0.68	1.36	1450808
2026-10-22	NVO	39.44	0.69	0.53	1472515
2026-10-23	NVO	39.03	0.69	0.64	1481126
2026-10-26	NVO	39.12	0.70	0.84	1458168
2026-10-27	NVO	38.66	0.70	0.37	1460362
2026-10-28	NVO	38.28	0.70	0.54	1463312
2026-10-29	NVO	39.15	0.70	0.69	1473695
2026-10-30	NVO	40	0.69	0.27	1486758
2026-11-02	NVO	40.46	0.68	0.93	1423055
2026-11-03	NVO	40.22	0.69	0.51	1471176
2026-11-04	NVO	42.17	0.69	0.30	1493175
2026-11-05	NVO	40.28	0.68	0.75	1544284
2026-11-06	NVO	40.3	0.68	0.55	1545593
2026-11-09	NVO	41.39	0.70	0.26	1486029
2026-11-10	NVO	40.69	0.68	0.70	1504557
2026-11-11	NVO	41.1	0.68	0.47	1514993
2026-11-12	NVO	40.63	0.68	0.69	1516553
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	NVO	38.13	2.7	-3425.3	3.34
2026-10-15	NVO	39.23	2.7	-2966.2	3.34
2026-10-16	NVO	38.82	2.7	-3670.4	3.37
2026-10-19	NVO	38.42	2.7	-3637.8	3.37
2026-10-20	NVO	38.42	2.7	-3637.8	3.37
2026-10-21	NVO	39.35	2.7	-3018.1	3.36
2026-10-22	NVO	39.45	2.7	-3333.2	3.36
2026-10-23	NVO	39.03	2.7	-3675.3	3.36
2026-10-26	NVO	39.12	2.7	-3265.7	22.39
2026-10-27	NVO	38.67	2.7	-3352.5	3.35
2026-10-28	NVO	38.29	2.7	-3317.2	3.34
2026-10-29	NVO	39.15	2.7	-2692.8	3.34
2026-10-30	NVO	39.81	2.7	-2963.6	3.34
2026-11-02	NVO	40.45	2.7	-3028.9	3.34
2026-11-03	NVO	40.37	2.7	-3124.7	3.36
2026-11-04	NVO	42.17	2.7	-2738.9	3.35
2026-11-05	NVO	40.25	2.7	-4266.5	22.39
2026-11-06	NVO	40.30	-28.7	-3356.3	22.39
2026-11-09	NVO	41.39	-28.7	-2623.9	3.34
2026-11-10	NVO	40.69	-28.7	-2723.0	3.35
2026-11-11	NVO	41.10	-19.3	-2562.6	3.51
2026-11-12	NVO	40.65	-19.3	-2489.0	3.48
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	NVO	0.00	-0.47	0.95
2026-10-15	NVO	0.00	-0.47	0.95
2026-10-16	NVO	0.00	-0.47	0.95
2026-10-19	NVO	0.00	-0.06	0.95
2026-10-20	NVO	0.00	-0.06	0.95
2026-10-21	NVO	0.00	-0.06	0.95
2026-10-22	NVO	0.00	-0.06	0.95
2026-10-23	NVO	0.00	-0.06	0.95
2026-10-26	NVO	0.00	-0.17	0.95
2026-10-27	NVO	0.00	-0.17	1.12
2026-10-28	NVO	0.00	-0.17	1.12
2026-10-29	NVO	0.00	-0.17	1.12
2026-10-30	NVO	0.00	-0.17	1.12
2026-11-02	NVO	0.00	-0.42	1.12
2026-11-03	NVO	0.00	-0.42	1.12
2026-11-05	NVO	0.00	-0.42	1.12
2026-11-06	NVO	0.00	-0.42	1.12
2026-11-09	NVO	0.00	-0.59	1.12
2026-11-10	NVO	0.00	-0.59	1.12
2026-11-11	NVO	0.00	-0.59	1.14
2026-11-12	NVO	0.00	-0.59	1.14
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.89

Avg. EPS Est. Current Quarter

0.73

Avg. EPS Est. Next Quarter

0.86

Insider Transactions

Institutional Transactions

-0.59

Beta

0.71

Average Sales Estimate Current Quarter

11812

Average Sales Estimate Next Quarter

10862

Fair Value

39.4

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

72.6

Max Drawdown 5-Year %

-74.7

Target Price

54.57

P/E

10.24

Forward P/E

11.98

PEG

70.47

P/S

2.62

P/B

5.43

P/Free Cash Flow

12.32

EPS

3.97

Average EPS Est. Cur. Y

3.48

EPS Next Y. (Est.)

3.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.98

Relative Volume

1.26

Return on Equity vs Sector %

25.6

Return on Equity vs Industry %

17.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.13

EBIT Estimation

-2489

◆ NVO Healthcare

$40.66

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

6/20

Pullback

17/25

Volume

1/15

Valuation

15/20

TP/AR

0/10

Options

7/10

RSI

53.2

Range 1M

49.2%

Sup Dist

0.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

2/25

Growth

4/30

Estimates

5/20

Inst/Vol

2/15

Options

5/10

EPS Yr

-5.4%

EPS NY

-1.4%

52W%

18.6%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +10% upside

Quality

24/30

Valuation

7/30

Growth

5/25

Stability

3/10

LT Trend

5/5

Upside

+10%

Quality

MoS

-3%

NVO — P/E HistoricalDrug Manufacturers - General

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 68794

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

ASND — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.62

Margin Of Safety %

-25

Put/Call OI Ratio

0.59

EPS Next Q Diff

EPS Last/This Y

14.25

EPS This/Next Y

-1.18

Price

266.47

Target Price

304.98

Analyst Recom

1.18

Performance Q

7.47

Upside

-36.1%

Beta

0.38

Ticker: ASND

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	ASND	227.18	0.47	1.07	12473
2026-10-15	ASND	226.49	0.46	11.37	12427
2026-10-16	ASND	225.05	0.47	1.93	12546
2026-10-19	ASND	228.59	0.54	0.18	9253
2026-10-20	ASND	234.28	0.52	1.60	9591
2026-10-21	ASND	238.84	0.52	1.39	9600
2026-10-22	ASND	242.79	0.52	0.90	9629
2026-10-23	ASND	243.27	0.52	1.33	9674
2026-10-26	ASND	244.15	0.52	0.08	9690
2026-10-27	ASND	245.94	0.52	1.05	9795
2026-10-28	ASND	249.86	0.54	0.52	9856
2026-10-29	ASND	252.95	0.57	1.04	10094
2026-10-30	ASND	251.04	0.59	0.18	10131
2026-11-02	ASND	248.87	0.59	0.14	10135
2026-11-03	ASND	250.28	0.59	1.67	10141
2026-11-04	ASND	258.06	0.59	0.40	10142
2026-11-05	ASND	253.27	0.59	0.21	10145
2026-11-06	ASND	256.77	0.58	0.44	10253
2026-11-09	ASND	259.68	0.58	0.08	10275
2026-11-10	ASND	255.59	0.58	0.59	10311
2026-11-11	ASND	259.21	0.58	1.68	10389
2026-11-12	ASND	267.02	0.59	0.60	10495
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	ASND	227.07	-	615.2	12.79
2026-10-15	ASND	226.54	-	613.1	12.79
2026-10-16	ASND	225.24	-	594.2	12.79
2026-10-19	ASND	229.76	-	614.6	12.79
2026-10-20	ASND	229.76	-	614.6	12.79
2026-10-21	ASND	234.16	-	630.7	12.79
2026-10-22	ASND	243.05	-	609.8	12.79
2026-10-23	ASND	243.19	-	595.4	12.79
2026-10-26	ASND	245.26	-	600.4	12.79
2026-10-27	ASND	245.99	-	596.8	11.32
2026-10-28	ASND	249.76	-	610.2	11.32
2026-10-29	ASND	253.04	-	603.5	10.08
2026-10-30	ASND	251.12	-	585.8	10.08
2026-11-02	ASND	248.95	-	584.0	10.08
2026-11-03	ASND	249.91	-	586.6	10.08
2026-11-04	ASND	257.95	-	614.3	10.08
2026-11-05	ASND	253.31	-	574.6	10.08
2026-11-06	ASND	256.77	-	601.1	10.08
2026-11-09	ASND	259.77	-	601.1	10.08
2026-11-10	ASND	256.56	-	579.2	10.08
2026-11-11	ASND	259.10	-	598.5	10.08
2026-11-12	ASND	266.47	-	615.3	10.08
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	ASND	-2.49	0.94	5.37
2026-10-15	ASND	-2.49	0.94	5.37
2026-10-16	ASND	-2.49	0.94	5.37
2026-10-19	ASND	-2.49	0.99	5.37
2026-10-20	ASND	-2.49	0.99	5.37
2026-10-21	ASND	-2.49	0.99	5.37
2026-10-22	ASND	-2.49	0.99	5.37
2026-10-23	ASND	-2.49	0.99	5.37
2026-10-26	ASND	-2.49	1.06	5.37
2026-10-27	ASND	-2.49	1.06	4.83
2026-10-28	ASND	-2.49	1.06	4.83
2026-10-29	ASND	-2.49	1.06	4.83
2026-10-30	ASND	-2.49	1.06	4.83
2026-11-02	ASND	-2.49	1.09	4.83
2026-11-03	ASND	-2.49	1.09	4.83
2026-11-05	ASND	-2.49	1.09	4.83
2026-11-06	ASND	-2.49	1.09	4.83
2026-11-09	ASND	-2.49	1.57	4.83
2026-11-10	ASND	-2.49	1.57	4.83
2026-11-11	ASND	-2.49	1.57	4.62
2026-11-12	ASND	-2.49	1.57	4.62
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.12

Avg. EPS Est. Next Quarter

1.42

Insider Transactions

-2.49

Institutional Transactions

1.57

Beta

0.38

Average Sales Estimate Current Quarter

365

Average Sales Estimate Next Quarter

410

Fair Value

199.02

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

5.6

Max Drawdown 5-Year %

Target Price

304.98

P/E

20.35

Forward P/E

26.34

PEG

P/S

14.37

P/B

10.68

P/Free Cash Flow

45.11

EPS

13.12

Average EPS Est. Cur. Y

10.08

EPS Next Y. (Est.)

8.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

70.99

Relative Volume

1.72

Return on Equity vs Sector %

25.2

Return on Equity vs Industry %

44.7

EPS 1 7Days Diff

-2.7

EPS 1 30Days Diff

-2.71

EBIT Estimation

615.3

◆ ASND Healthcare

$267.07

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

6/25

Volume

3/15

Valuation

10/20

TP/AR

2/10

Options

5/10

RSI

70.2

Range 1M

93.9%

Sup Dist

4.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

13/25

Growth

19/30

Estimates

3/20

Inst/Vol

8/15

Options

8/10

EPS Yr

485.6%

EPS NY

-36.9%

52W%

83.8%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -33.2% upside

Quality

29/30

Valuation

2/30

Growth

11/25

Stability

7/10

LT Trend

4/5

Upside

-33.2%

Quality

MoS

-25%

ASND — P/E HistoricalBiotechnology

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1189

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ASND

Latest News

—

Caricamento notizie per ASND…

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y